Non-obstructive Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Conditions
Keywords
CPAP, Hypertrophic cardiomyopathy, Blood Pressure, The focus of the present study is to evaluate the acute hemodynamic effects of CPAP in patients with non-obstructive and obstructive hypertrophic cardiomyopathy
Brief summary
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%. Obstructive sleep apnea (OSA) is extremely common among patients with established cardiovascular disease, including hypertension and atrial fibrillation and when present may contribute to worse cardiovascular outcome. Although patients with HCM do not necessarily have typical characteristics of patients with OSA, such as obesity and increasing age, there is recent evidence that OSA is extremely common among patients with HCM, with a prevalence ranging from 32% to 71%. The presence of OSA among patients with HCM is independently associated with worse structural and functional impairment of the heart, including atrial and aorta enlargement, worse New York Heart Association functional class, and worse quality of life. Therefore, the recognition and treatment of OSA is a new area of research that may impact in the management of patients with HCM.
Interventions
A low or high CPAP pressure is delivered for 20 minutes
Sponsors
Study design
Eligibility
Inclusion criteria
* both genders * over 18 years-old * hemodynamically stable * with no other cardiac disease * consent form signed
Exclusion criteria
* presence of pacemaker * spontaneous withdrawal * previous cardiorespiratory arrest * atrial fibrilation during echocardiography
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cadiac performance by echocardiography | acutely |
Countries
Brazil